References
- Spear BB , Heath-ChiozziM , HuffJ. Clinical application of pharmacogenetics. Trends Mol. Med.7(5), 201–204 (2001).
- Pirmohamed M , JamesS , MeakinSet al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ329(7456), 15–19 (2004).
- Davies EC , GreenCF , TaylorS , WilliamsonPR , MottramDR , PirmohamedM. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS ONE4(2), e4439 (2009).
- NHS England . Medicines Value Programme. (2020). https://www.england.nhs.uk/medicines/value-programme/
- UK Pharmacogenetics and Stratified Medicine Network . Pharmacogenetics in the NHS workshop presentations. (2018). http://www.uk-pgx-stratmed.co.uk/index.php/february-2018-workshop-videos
- FDA . Table of pharmacogenomic biomarkers in drug labeling. (2020). https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
- Bank PCD , CaudleKE , SwenJJet al. Comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clin. Pharmacol. Ther.103(4), 599–618 (2018).
- Relling MV , EvansWE. Pharmacogenomics in the clinic. Nature526(7573), 343–350 (2015).
- Genomics England . The 100,000 Genomes Project. (2020). https://www.genomicsengland.co.uk/about-genomics-england/the-100000-genomes-project/
- Genomics England . How can we make cancer treatment less toxic? (2020). https://www.genomicsengland.co.uk/how-can-we-make-cancer-treatment-less-toxic/
- Centre for Addiction and Mental Health . Individualized medicine: pharmacogenetic assessment & clinical treatment. (2020). http://impact.camhx.ca/en/home.php#
- Osanlou O , PirmohamedM , DalyAK. Pharmacogenetics of adverse drug reactions. Adv. Pharmacol.83, 155–190 (2018).
- Pirmohamed M , OstrovDA , ParkBK. New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity. J. Allergy Clin. Immunol.136(2), 236–244 (2015).
- Plumpton CO , PirmohamedM , HughesDA. Cost-effectiveness of panel tests for multiple pharmacogenes associated with adverse drug reactions: an evaluation framework. Clin. Pharmacol. Ther.105(6), 1429–1438 (2019).
- Alfirevic A , PirmohamedM. Genomics of adverse drug reactions. Trends Pharmacol. Sci.38(1), 100–109 (2017).
- Rauch A , NolanD , MartinA , McKinnonE , AlmeidaC , MallalS. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Infect. Dis.43(1), 99–102 (2006).
- Pavlos R , MallalS , OstrovDet al. T cell-mediated hypersensitivity reactions to drugs. Annu. Rev. Med.66, 439–454 (2015).
- Kapoor R , Martinez-VegaR , DongDet al. Reducing hypersensitivity reactions with HLA-B*5701 genotyping before abacavir prescription: clinically useful but is it cost-effective in Singapore? Pharmacogenet. Genomics 25(2), 60–72 (2015).
- Tan O , ShresthaR , CunichM , SchofieldDJ. Application of next-generation sequencing to improve cancer management: a review of the clinical effectiveness and cost–effectiveness. Clin. Genet.93(3), 533–544 (2018).
- Pirmohamed M , BurnsideG , ErikssonNet al. A randomized trial of genotype-guided dosing of warfarin. N. Engl. J. Med.369(24), 2294–2303 (2013).
- Zhou Y , ArmsteadAR , CoshattGM , LimdiNA , HaradaS. Comparison of two point-of-care CYP2C19 genotyping assays for genotype-guided antiplatelet therapy. Ann. Clin. Lab. Sci.47(6), 738–743 (2017).
- van der Wouden CH , BohringerS , CecchinEet al. Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. Pharmacogenet. Genomics30(6), 131–144 (2020).
- van der Wouden CH , Cambon-ThomsenA , CecchinEet al. Implementing pharmacogenomics in Europe: design and implementation strategy of the Ubiquitous Pharmacogenomics Consortium. Clin. Pharmacol. Ther.101(3), 341–358 (2017).
- Rasmussen-Torvik LJ , StallingsSC , GordonASet al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin. Pharmacol. Ther.96(4), 482–489 (2014).
- NHS England . NHS genomic medicine service. (2020). https://www.england.nhs.uk/genomics/nhs-genomic-med-service/
- NHS England . Sustainability and transformation partnerships. (2020). https://www.england.nhs.uk/integratedcare/stps/
- Miller DM , DalyC , AboelsaodEMet al. Genetic epidemiology of malignant hyperthermia in the UK. Br. J. Anaesth.121(4), 944–952 (2018).
- Cicali EJ , WeitzelKW , ElseyARet al. Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene–drug pairs across ambulatory care settings. Genet. Med.21(10), 2264–2274 (2019).
- Wang L , WeinshilboumR. Pharmacogenomics in practice. Clin. Pharmacol. Ther.106(5), 936–938 (2019).
- Hoffman JM , HaidarCE , WilkinsonMRet al. PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics. Am. J. Med. Genet. C Semin. Med. Genet.166C(1), 45–55 (2014).
- Bell GC , CrewsKR , WilkinsonMRet al. Development and use of active clinical decision support for preemptive pharmacogenomics. J. Am. Med. Inform. Assoc.21(e1), e93–e99 (2014).
- Just KS , SteffensM , SwenJJ , PatrinosGP , GuchelaarHJ , StinglJC. Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx). Eur. J. Clin. Pharmacol.73(10), 1247–1252 (2017).
- Higgs JE , AndrewsJ , GurwitzD , PayneK , NewmanW. Pharmacogenetics education in British medical schools. Genomic Med.2(3–4), 101–105 (2008).
- Maxwell SRJ , ColemanJJ , BollingtonL , TaylorC , WebbDJ. Prescribing Safety Assessment 2016: delivery of a national prescribing assessment to 7343 UK final-year medical students. Br. J. Clin. Pharmacol.83(10), 2249–2258 (2017).
- Health Education England . HEE Genomics Education Programme. (2020). https://www.genomicseducation.hee.nhs.uk/